Multidrug-resistant HIV-1 infection despite preexposure prophylaxis

New England Journal of Medicine

Volumn 376, Issue 5, 2017, Pages 501-502

  Knox, David C ^a   Anderson, Peter L ^b   Harrigan, P Richard ^c   Tan, Darrell H S ^d  

^a MAPLE LEAF MEDICAL CLINIC   (Canada)

^b UNIVERSITY OF COLORADO   (United States)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ADULT; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; LETTER; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; TREATMENT DURATION; GENE; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; PRE-EXPOSURE PROPHYLAXIS; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; GENES, MDR; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PRE-EXPOSURE PROPHYLAXIS;

EID: 85011838865     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1611639     Document Type: Letter

References (5)

1. Grant RM, Anderson PL, McMahan V, et al. Uptake of preexposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A cohort study. Lancet Infect Dis 2014; 14: 820-9.
2. Knox DC, Anderson PL, Harrigan PR, Tan DHS. HIV-1 infection with multi-class resistance despite pre-exposure prophylaxis (PrEP). Presented at the 23rd Conference on Retroviruses and Opportunistic Infections, Boston, February 22-25 2016.
3. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102(5B): 117-26.
4. Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses 2013; 29: 384-90.
5. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, et al. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: Implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 2009; 200: 687-97.